Recital 28, Regulation (EU) 2025/2086

In forcesince 17 Oct 2025

In order to ensure transparency, on the one hand, and the protection of confidential data for commercial reasons, on the other hand, the joint clinical assessment and the summary reports, together with the documentation referred to in Article 30(3), points (d) and (i), of Regulation (EU) 2021/2282, should be published, after having considered the views of the JCA Subgroup as to the commercially sensitive nature of the information contained in that documentation, which the health technology developer has requested to be treated as confidential.